Growing evidence has demonstrated that FOXM1 is frequently overexpressed in breast cancer, lung cancer, hepatocellular carcinoma, glioblastoma and pancreatic cancer. This evidence concerns the gene FOXM1 and familial pancreatic carcinoma.